Page 27 - P4403.14_V92_YOUROTC_Book MAY_2024 NI
P. 27

HEALTHCARE  27

















             Be her pharmacy



                               answers


                               guidance


                               solution



                               comfort


                Brand
            Support Deal       support
              Available
             for Numark
              Members
                                         Standard                   Numark Brand Support Deal
                                                         Numark   Numark   % off trade  POR % after   Max no. of
             Product     Size  Case   Buying   RRP  Trade    POR   brand support  member Net   for Numark  Numark brand  packs rebated   Pip Code
                             Size  Price/Single   Offer %  %  rebate  price   members  support  per month
             ELLAONE
               ellaOne 30mg  1  1  £12.67  £34.95  10%  56%  £2.94  £9.73  31%     71%      15    347-8708
           Numark Brand Support Terms and Conditions apply as per your Numark membership agreement and can be found on NumarkNet
           https://numarknet.com/about-numark/terms-and-conditions/terms-of-sale/brand-support-terms-and-conditions








                                      Save
             SCAN FOR
             TRAINING               10%        Off            2.5x more effective
                                     Trade                          than levonorgestrel            1



                                                                  Support your pharmacy to help women
                                                                     with their contraceptive needs

            perrigowomenshealth.co.uk                               1. Glasier A et al. Lancet 2010; 375(9714):555-62.



           ESSENTIAL INFORMATION:
           PRODUCT INFORMATION: ellaOne® 30 mg film-coated tablet (ulipristal acetate). Refer to the SmPC for further information. INDICATION: Emergency contraception (EC) within 120 hours (5 days)
           of unprotected sexual intercourse or contraceptive failure. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://
           mhraproducts4853. blob.core.windows.net/docs/b0731d06d3693ecfbd3c4d15547cba88d0f7de6c MARKETING AUTHORISATION HOLDER: Laboratoire HRA Pharma, 200 avenue de Paris, 92320
           Châtillon, France. MARKETED IN THE UK BY: HRA Pharma a Perrigo Company, One Embassy Gardens, Viaduct Gardens, Nine Elms, London SW11 7BW, United Kingdom LEGAL CATEGORY: P
           Date of last revision of text: October 2023. Unique ID: UK/ELLA/1672
                          Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
                            Adverse events should also be reported to HRA Pharma on 0800 917 9548 or email HRA-UK@cambreg.co.uk
           Date of preparation: February 2024. Code: UK/ELLA/1719.
   22   23   24   25   26   27   28   29   30   31   32